Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels

被引：37

作者：

Peattie, Robert A. ^{[1
]}

Pike, Daniel B.

Yu, Bolan ^{[2
]}

Cai, Shenshen ^{[2
]}

Shu, Xiao Zheng ^{[2
]}

Prestwich, Glenn D. ^{[2
]}

Firpo, Matthew A. ^{[3
]}

Fisher, Robert J. ^{[4
]}

机构：

[1] Tufts Univ, Ctr Sci & Technol, Dept Biomed Engn, Medford, MA 02155 USA

[2] Univ Utah, Dept Med Chem, Ctr Therapeut Biomat, Salt Lake City, UT 84112 USA

[3] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA

[4] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

来源：

DRUG DELIVERY | 2008年 / 15卷 / 06期

关键词：

angiogenesis; controlled drug release; glycosaminoglycans; growth factors; cytokine;

D O I：

10.1080/10717540802035442

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The hypothesis that incorporation of small amounts (0.3% w/w) of modified heparin in thiol-modified hyaluronan or HA and gelatin hydrogels would regulate release of cytokine growth factors (GFs) from those gels has been investigated in vitro. In addition, the physiologic response to gel implantation has been evaluated in vivo. Tests were performed with 6 GFs: basic fibroblast growth factor (bFGF), vascular endothelial growth factor ( VEGF), angiopoietin-1 (Ang-1), keratinocyte growth factor, platelet-derived growth factor-AA ( PDGF), and transforming growth factor-beta 1. Release profiles for all 6 over several weeks were well fit by first order exponential kinetics (R(2) > 0.9 for all cases). The most remarkable result of the experiment was a dramatic variation in the total mass ultimately released, which varied from as much as 90.2% of the initial load for bFGF to as little as 1.8% for PDGF, a 45-fold difference. Furthermore, gels containing either VEGF of Ang-1 produced twice the vascularization response in vivo as gels not containing a growth factor. Thus, those GFs maintained strong physiologic effectiveness.

引用

页码：389 / 397

页数：9

共 21 条

[11] NOVEL HYDROGELS OF HYALURONIC-ACID - SYNTHESIS, SURFACE-MORPHOLOGY, AND SOLID-STATE NMR [J].

POUYANI, T ;

HARBISON, GS ;

PRESTWICH, GD .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (17) :7515-7522

[12]

Prestwich G.D., 1998, PHARM SCI TECHNOL TO, V1, P42

[13]

PRESTWICH GD, 2005, HYALURONAN STRUCTURE, V1, P409

[14]

Prestwich GD, 2006, ADV EXP MED BIOL, V585, P125

[15]

Robinson CJ, 2001, J CELL SCI, V114, P853

[16] Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel [J].

Shu, XZ ;

Ghosh, K ;

Liu, YC ;

Palumbo, FS ;

Luo, Y ;

Clark, RA ;

Prestwich, GD .

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2004, 68A (02) :365-375

[17] Disulfide cross-linked hyaluronan hydrogels [J].

Shu, XZ ;

Liu, YC ;

Luo, Y ;

Roberts, MC ;

Prestwich, GD .

BIOMACROMOLECULES, 2002, 3 (06) :1304-1311

[18] In situ crosslinkable hyaluronan hydrogels for tissue engineering [J].

Shu, XZ ;

Liu, YC ;

Palumbo, FS ;

Lu, Y ;

Prestwich, GD .

BIOMATERIALS, 2004, 25 (7-8) :1339-1348

[19]

SOKER S, 1993, J BIOL CHEM, V268, P7685

[20] Synthesis and in vitro degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid [J].

Vercruysse, KP ;

Marecak, DM ;

Marecek, JF ;

Prestwich, GD .

BIOCONJUGATE CHEMISTRY, 1997, 8 (05) :686-694

← 1 2 3 →